Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03398837 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Phase 3 study, sponsored by Corbus Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
NCT03398837 is a Phase 3 study that was terminated before completion, run by Corbus Pharmaceuticals. The registered enrollment target is 365 participants.
The verdict
NCT03398837, a Phase 3 study, was terminated before completion, sponsored by Corbus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
Study Summary
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites in North America, Europe, Australia, and Asia. The planned duration of treatment with study drug is 52 weeks.
Interventions
- OTHER Placebo oral capsule
- DRUG Lenabasum 20 mg
- DRUG Lenabasum 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03398837
The ClinicalTrials.gov registry entry for NCT03398837 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corbus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03398837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03398837 about?
NCT03398837 is a clinical study titled "Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis". This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites in North America, Europe, Aust...
What is the current status of trial NCT03398837?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2017-12-18. Estimated completion is 2020-12-21.
What interventions are being tested in trial NCT03398837?
The interventions under investigation include: Placebo oral capsule (OTHER), Lenabasum 20 mg (DRUG), Lenabasum 5 mg (DRUG).
Who is sponsoring clinical trial NCT03398837?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.